Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
| ▸ | SDHA | P31040 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1034798 | 1.00 | MAOA (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL12956468 | 0.91 | F10 (0.54) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13428648 | 0.88 | F10 (0.66) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL12956275 | 0.88 | MAOA (0.55) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL13150849 | 0.88 | MAOA (0.49) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1033024 | 0.87 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL1033023 | 0.87 | MAOA (0.70) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5917645 | 0.85 | MAOA (0.56) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL5917566 | 0.85 | MAOB (0.71) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL16737267 | 0.85 | MAOA (0.50) | MAOAMAOBLMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | MELINTA SUBSIDIARY CORP. | 2015-06-11 | — | — | US | disclosed |
| US-8796465-B2 | Process for the syntheses of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8399660-B2 | Process for the synthesis of triazoles | RIB-X PHARMACEUTICALS, INC. (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1904489-B1 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB X PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100234615-A1 | Process for the synthesis of triazoles | MELINTA SUBSIDIARY CORP. | 2010-09-16 | — | — | US | disclosed |
| EP-1904489-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | Rib-X Pharmaceuticals, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234615-A1 | Process for the synthesis of triazoles | PROKR1, SI, IL33 | MAOA 1726/4885MAOB 1344/4885LMNA 2397/4885 |
| US-20140031402-A1 | Process for the Syntheses of Triazoles | PROKR1, VIP, SI | MAOA 1794/4885MAOB 1380/4885LMNA 2527/4885 |
| US-20150158827-A1 | Process for the Synthesis of Triazoles | PROKR1, SI, IL33 | MAOA 1726/4885MAOB 1344/4885LMNA 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.